Business
Appointment of Chief Financial Officer and Bo...
4basebio PLC has appointed Richard Bungay as Chief Financial Officer, effective July 2026, bringing extensive experience in fundraising, M&A, and strategic finance within the biotech sector, including a $670 million Series A raise and a $1.5 billion acquisition. This appointment coincides with board changes, including the departure of Alexander Link and Alan Malus, with Dr. Heikki Lanckriet taking over Mr. Link's role and Cornel Chiriac expected to replace Mr. Malus pending approvals. The company anticipates Bungay's expertise will be crucial as it enters a phase of accelerated commercial growth for its synthetic DNA manufacturing services. Disclaimer*
About this update from 4basebio Plc
[{"type":"text","content":"\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n 4basebio PLC\n \n \n \n \n \n \n \n \n \n \n \n \n (\"4basebio\" or the \"Company\")\n \n \n \n \n \n \n \n \n \n \n \n \n \n Appointment of Chief Financial Officer and Board Changes\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Cambridge, UK, 14 May 2026\n \n \n \n \n \n \n \n –4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the appointment of Richard Bungay as Chief Financial Officer, with effect from July 2026. Richard takes over the role from David Roth, who stepped down from the Board earlier this year and remained working with the Company over the orderly handover period. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Richard is an accomplished leader with over 30 years’ senior finance and strategic experience within the pharmaceutical and biotechnology sector, leading both public and private companies from research through all clinical phases, regulatory approval and commercialisation. He joins 4basebio from Sitala Bio Limited, a UK-based private biotech where he helped lead a strategic repositioning of the business, working closely with the CEO and board to raise a signficant Series A round and execute an in-licencing deal with Fosun Pharma for up to $670m.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Richard’s prior roles include CEO and CFO at Diurnal Group plc, where he led its acquisition by Neurocrine Biosciences, Inc. (Nasdaq: NBIX) in 2022 at a 147% one-day premium, CEO and CFO at Mereo Biopharma Group plc (NASDAQ: MREO), where he helped in-license a portfolio from Novartis and subsequently completed its AIM IPO, and CFO at Verona Pharma (then listed on the London Stock Exchange, now a subsidiary of Merck & Co) where he helped recapitalise the company.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Earlier in his career Richard was the Director of Corporate Communications and Strategic Planning at Celltech Group plc, a London-listed FTSE-100/250 company where he helped execute its acquisition by UCB for £1.5bn. \n \n \n \n \n \n \n \n \...